Boehringer Ingelheim: BI 3034701 triple GLP‑1/GIP/NPY2 agonist enters Phase II

Phase II launch

Boehringer Ingelheim has started a Phase II clinical trial of BI 3034701 to evaluate efficacy and safety in people living with obesity and overweight. The study includes dose‑finding and broader clinical evaluation; the trial is listed as NCT07662122.

Modality and mechanism

BI 3034701 is a potential first‑in‑class triple agonist designed to activate GLP‑1, GIP and NPY2 receptors. The molecule aims to combine GLP‑1/GIP‑mediated satiety, weight reduction and metabolic regulation with NPY2R‑driven central modulation of hunger, appetite and food intake.

Clinical data and development partners

In Phase I studies BI 3034701 demonstrated a generally favorable safety and tolerability profile, supporting advancement to mid‑stage development. The candidate was developed in cooperation with Gubra; Boehringer Ingelheim is solely responsible for further development and global commercialization.

Portfolio context and public‑health backdrop

BI 3034701 is part of Boehringer Ingelheim’s expanding obesity and cardiometabolic portfolio, which also includes survodutide, a glucagon/GLP‑1 dual agonist whose Phase III results were presented at the American Diabetes Association 2026 Scientific Sessions. The company frames this work against the global burden of overweight and obesity, noting more than 1.9 billion adults lived with overweight in 2016 and that over one billion people were living with obesity globally (about 1 in 8).